Looking for a specific product?

Make a search for products & suppliers, articles & news.

Bionor Pharma Positioned for Execution of the Kick, the Kill and the Boost Strategy, Aiming Towards a Functional Cure for HIV

Bionor Pharma ASA (OSE: BIONOR) announced today results from the third quarter and first nine months of 2013. 

The Q3 report will be presented by webcast 8 November at 8.30 am CET. Link for registration and access to the webcast: http://www.media-server.com/m/p/zovaz8yn
See further information about the webcast and call numbers below.

Download the Q3 report and Q3 presentation.

 

If you would like to find out more about Bionor Pharma, please visit their website here.

Associated companies:


Related news

Latest news

Over 45,000 businesses risk EU energy fines for non-compliance

The previous compliance date of 5th December 2015,

“An Incredibly reliable net cleaning system”

Our predator nets are prone to fouling with scallops and mussels,

“An Incredibly reliable net cleaning system”

Good knowledge enables the customer to get the most out of the product. 

DNV GL initiates energy storage standard for Australia

DNV GL will lead the project and prepare a draft proposal for the standard,

Kvale acts for foreign ship owners in a direct action case

The case is against a Norwegian P&I underwriter and the alleged tortfeasor following a collision in the Singapore strait. Recently, the Supreme Court rendered a verdict on the issue of whether Norwegian courts hav...

Kvale recognized by IAM Patent 1000 2018

Kvale's IP-team receives great review from IAM Patent 1000 "The world's leading patent professionals 2018". 

Positive winds at the SeaWork International trade fair

- This is the place to be,

DNV GL and Brodosplit sign class contract for Quark polar expedition vessel

Quark has a long history of civilian polar exploration.

Elkem sustainability magazine 2017 and GRI report for 2017 is ready

Corporate social responsibility is one of the building...